Hereditary ataxia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hereditary ataxia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 FEDAES https://clinicaltrials.eu/organisation/fedaes/ Tue, 02 Jun 2026 10:00:16 +0000 https://clinicaltrials.eu/organisation/fedaes/ FEDAES (Federación de Ataxias de España) is a Spanish federation supporting people with ataxia, rare neurological disorders that cause loss of motor coordination. The organization provides psychological support, speech therapy, online physiotherapy, support groups, and workshops, and also promotes research and social awareness.

]]> Study of fampridine treatment for patients with spinocerebellar ataxia SCA27B caused by FGF14 gene mutation https://clinicaltrials.eu/trial/study-of-fampridine-treatment-for-patients-with-spinocerebellar-ataxia-sca27b-caused-by-fgf14-gene-mutation/ Wed, 29 Apr 2026 15:07:12 +0000 https://clinicaltrials.eu/trial/study-of-fampridine-treatment-for-patients-with-spinocerebellar-ataxia-sca27b-caused-by-fgf14-gene-mutation/ This study focuses on patients with Spinocerebellar Ataxia, specifically type SCA27B, which is a rare genetic condition affecting movement and balance due to problems in a part of the brain called the cerebellum. The study will test a medication called Fampridine, given as prolonged-release tablets, to see if it can help improve symptoms in people with this condition.

The main purpose of this research is to determine if taking Fampridine tablets twice daily for 12 weeks helps patients with SCA27B. During the study, some patients will receive Fampridine while others will receive placebo. The medication or placebo will be taken by mouth, with a maximum daily dose of 20 mg of Fampridine for those in the treatment group.

The study will last 16 weeks in total, including a 12-week treatment period followed by 4 weeks of observation after stopping the medication. Throughout the study, doctors will monitor various aspects of the participants’ movement abilities, balance, daily activities, and overall well-being. They will also check for any potential side effects through regular medical examinations and blood tests.

]]> Study on the Safety of VO659 for Patients with Spinocerebellar Ataxia Types 1, 3, and Huntington’s Disease https://clinicaltrials.eu/trial/study-on-the-safety-of-vo659-for-patients-with-spinocerebellar-ataxia-types-1-3-and-huntingtons-disease/ Wed, 29 Apr 2026 14:58:01 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-vo659-for-patients-with-spinocerebellar-ataxia-types-1-3-and-huntingtons-disease/ This clinical trial is focused on studying the safety and tolerability of a new treatment called VO659 for people with certain neurological conditions. The diseases being studied are Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, and Huntington’s Disease. These are conditions that affect the brain and can lead to problems with movement and coordination. The treatment, VO659, is a type of medication known as an antisense oligonucleotide, which is designed to target specific genetic material in the body. It is administered as a solution through an injection into the space around the spinal cord, known as an intrathecal injection.

The purpose of this study is to evaluate how safe and well-tolerated multiple doses of VO659 are when given to participants with these conditions. Participants will receive the treatment in increasing doses to observe how their bodies respond. The study will monitor various health parameters, including physical and neurological examinations, vital signs, and laboratory tests, to ensure the safety of the participants. The study will also look at how the body processes the medication, including how long it stays in the body and how it is eliminated.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and any potential side effects. The study aims to gather important information that could lead to new treatment options for people with Spinocerebellar Ataxia and Huntington’s Disease. This research is an important step in understanding how VO659 can be used to help manage these challenging conditions.

]]> Study on Trehalose Dihydrate for Treating Spinocerebellar Ataxia in Adults https://clinicaltrials.eu/trial/study-on-trehalose-dihydrate-for-treating-spinocerebellar-ataxia-in-adults/ Wed, 29 Apr 2026 14:25:01 +0000 https://clinicaltrials.eu/trial/study-on-trehalose-dihydrate-for-treating-spinocerebellar-ataxia-in-adults/ This clinical trial is focused on studying a condition called Spinocerebellar Ataxia type-3 (SCA3), which affects the brain and can lead to problems with movement and coordination. The study is testing a new treatment called SLS-005, which is a solution given through an intravenous infusion. The main ingredient in this treatment is trehalose dihydrate, a type of sugar that is being investigated for its potential benefits in treating SCA3.

The purpose of the study is to determine how effective SLS-005 is in treating adults with SCA3. Participants in the study will receive either the SLS-005 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for about a year, during which participants will receive regular infusions and attend follow-up visits to monitor their health and any changes in their condition.

Throughout the study, researchers will assess various aspects of the participants’ health, including their ability to perform daily activities and any changes in their symptoms. The goal is to see if SLS-005 can improve the quality of life for people with SCA3 by reducing the severity of their symptoms. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety during the trial.

]]>